Abstract
Dual antiplatelet therapy (DAT) with aspirin and clopidogrel is the standard regimen to achieve rapid platelet inhibition and prevent thrombotic events. Currently, little information is available regarding alternative antiplatelet therapy in patients with an allergy or intolerance to aspirin. Although cilostazol is already a common alternative to aspirin in clinical practice in China, its efficacy and safety remain to be determined. We retrospectively analyzed 613 Chinese patients who had undergone primary percutaneous coronary intervention (PCI). Among them, 405 patients received standard DAT (aspirin plus clopidogrel) and 205 patients were identified with intolerance to aspirin and received alternative DAT (cilostazol plus clopidogrel). There were no significant differences between the two groups in their baseline clinical characteristics. The main outcomes of the study included major adverse cardiac events (MACEs) and bleeding events during 12 months of follow-up. The MACEs endpoint was reached in 10 of 205 patients treated with cilostazol (4.9%) and in 34 of 408 patients treated with aspirin (8.3%). No statistically significant difference was observed in MACEs between the two groups. However, patients in the cilostazol group had less restenosis than did patients in the aspirin group (1.5% vs 4.9%, P=0.035). The occurrence of bleeding events tended to be lower in the cilostazol group (0.49% vs 2.7%, P=0.063). These clinical observations were further analyzed using network system pharmacology analysis, and the outcomes were consistent with clinical observations and preclinical data reports. We conclude that in Chinese patients with aspirin intolerance undergoing coronary stent implantation, the combination of clopidogrel with cilostazol may be an efficacious and safe alternative to the standard DAT regimen.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Solinas E, Dangas G, Kirtane AJ, Lansky AJ, Franklin-Bond T, Boland P, et al. Angiographic patterns of drug-eluting stent restenosis and one-year out-comes after treatment with repeated percutaneous coronary intervention. Am J Cardiol 2008; 102: 311–5.
Daemen J, Wenaweser P, Tsuchida K, Ab-recht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007; 369: 667–78.
Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE . Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356: 1020–9.
Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607–21.
Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179–89.
Cohen M . Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond. Catheter Cardiovasc Interv 2009; 74: 579–97.
Feng CH, White AA, Stevenson DD . Characterization of aspirin allergies in patients with coronary artery disease. Ann Allergy Asthma Immunol 2013; 110: 92–5.
Newby LK, Bhapkar MV, White HD . Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation. J Thromb Thrombolysis 2003; 16: 119–28.
Latib A, Ielasi A, Ferri L, Chieffo A, Godino C, Carlino M, et al. Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: A proposed alternative regimen. Int J Cardiol 2013; 165: 444–7.
Cook KA, White AA . Rapid aspirin challenge in patients with aspirin allergy and acute coronary syndromes. Curr Allergy Asthma Rep 2016; 16: 11.
Cone J, Wang S, Tandon N, Fong M, Sun B, Sakurai K, et al. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J Cardiovasc Pharmacol 1999; 34: 497–504
Guerra E, Byrne RA, Kastrati A . Pharmacological inhibition of coronary restenosis: systemic and local approaches. Expert Opin Pharmacother 2014; 15: 2155–71.
Jang JS, Jin HY, Seo JS, Yang TH, Kim DK, Kim DS, et al. A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation. Cardiology 2012; 122: 133–43.
Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol 2007; 100: 1103–8.
Goto S . Cilostazol: potential mechanism of action for anti-thrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl 2005; 6: 3–11.
Takeuchi K, Takayama S, Izuhara C . Comparative effects of the anti-platelet drugs, clopidogrel, ticlopidine, and cilostazol on aspirin-induced gastric bleeding and damage in rats. Life Sci 2014; 110: 77–85.
Porto I, D'Amario D, Crea F . Cilostazol and primary-PCI: mirage or good alternative? Curr Vasc Pharmacol 2012; 10: 468–71.
Matic DM, Milasinovic DG, Asanin MR, Mrdovic IB, Marinkovic JM, Kocev NI, et al. Prognostic implications of bleeding measured by Bleeding Academic Research Consortium (BARC) categorisation in patients undergoing primary percutaneous coronary intervention. Heart 2014; 100: 146–52.
Zhang H, Ma S, Feng Z, Wang D, Li C, Cao Y, et al. Cardiovascular disease chemogenomics knowledgebase-guided target identification and drug synergy mechanism study of an herbal formula. Sci Rep 2016; 28: 6
Zhang Y, Wang L, Feng Z, Cheng H, McGuire TF, Ding Y, et al. StemCellCKB: an integrated stem cell-specific chemogenomics knowledgebase for target identification and systems-pharmacology research. J Chem Inf Model 2016; 56: 1995–2004
Liu H, Wang L, Lv M, Pei R, Li P, Pei Z, et al. AlzPlatform: an Alzheimer's disease domain-specific chemogenomics knowledgebase for polypharmacology and target identification research. J Chem Inf Model 2014; 54: 1050–60
Feng Z, Pearce LV, Xu X, Yang X, Yang P, Blumberg PM, et al. Structural insight into tetrameric hTRPV1 from homology modeling, molecular docking, molecular dynamics simulation, virtual screening, and bioassay validations. J Chem Inf Model 2015; 55: 572–88.
Ma C, Wang L, Xie XQ . Ligand classifier of adaptively boosting ensemble decision stumps (LiCABEDS) and its application on modeling ligand functionality for 5-HT-subtype GPCR families. J Chem Inf Model 2011; 51: 521–31.
Ma C, Wang L, Xie XQ . GPU accelerated chemical similarity calculation for compound library comparison. J Chem Inf Model 2011; 51: 1521–7.
Wang L, Ma C, Wipf P, Liu H, Su W, Xie XQ . TargetHunter: an in silico target identification tool for predicting therapeutic potential of small organic molecules based on chemogenomic database. AAPS J 2013; 15: 395–406.
Xu X, Ma S, Feng Z, Hu G, Wang L, Xie XQ . Chemogenomics knowledgebase and systems pharmacology for hallucinogen target identification-Salvinorin A as a case study. J Mol Graph Model 2016; 70: 284–95.
Abdur Rahim M, Praveen Rao PN, Bhardwaj A, Kaur J, Huang Z, Knaus EE . Isomeric acetoxy analogs of celecoxib and their evaluation as cyclooxygenase inhibitors. Bioorg Med Chem Lett 2011; 21: 6074–80.
Abdellatif KR, Chowdhury MA, Dong Y, Das D, Yu G, Velázquez CA, et al. Dinitroglyceryl and diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of aspirin, indomethacin and ibuprofen: synthesis, biological evaluation and nitric oxide release studies. Bioorg Med Chem Lett 2009; 19: 3014–8.
Latib A, Ielasi A, Ferri L, Chieffo A, Godino C, Carlino M, et al. Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: a proposed alternative regimen. Int J Cardiol 2013; 165: 444–7.
Agarwal SK . Single antiplatelet therapy after percutaneous coronary intervention in patients allergic to aspirin. Cardiovasc Revasc Med 2014; 15: 308–10.
Meadows TA, Bhatt DL . Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007; 100: 1261–75.
Sallustio F, Rotondo F, Di Legge S, Stanzione P . Cilostazol in the management of atherosclerosis. Curr Vasc Pharmacol 2010; 8: 363–72.
Lee SW, Park SW, Hong MK, Kim YH, Lee BK, Song JM, et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 2005; 46: 1833–7.
Lee SW, Park SW, Yun SC, Kim YH, Park DW, Kim WJ, et al. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: rug-luting stenting followed by cilostazol treatment reduces adverse serious cardiac Events (DECREASE registry). Am Heart J 2010; 159: 284–91.
Han Y, Li Y, Wang S, Jing Q, Wang Z, Wang D, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009; 157: 733–9.
Biondi-Zoccai GGL, Lotrionte M, Anselmino M, Moretti C, Agostoni P, Testa L, et al. Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J 2008; 155: 1081–9.
Douglas JS Jr. Role of adjunct pharmacologic therapy in the era of drug-eluting stents. Atheroscler Suppl 2005; 6: 47–52.
Douglas JS, Holmes DR, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, et al. Cilostazol for Restenosis Trial (CREST) Investigators. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005; 112: 2826–32.
Park SW, Lee CW, Kim HS, Lee NH, Nah DY, Hong MK, et al. Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol 2000; 86: 499–503.
Lee S W, Park S W, Kim Y H, Yun S C, Park D W, Lee C W, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (a randomized comparison of triple antiplatelet therapy with dual antiplatelet therapy after drug-eluting stent implantation in diabetic patients). J Am Coll Cardiol 2008; 51: 1181–7.
Kunishima T, Musha H, Eto F, Iwasaki T, Nagashima J, Masui Y, et al. A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. Clin Ther 1997; 19: 1058–66.
Take S, Matsutani M, Ueda H, Hamaguchi H, Konishi H, Baba Y, et al. Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1997; 79: 1097–9.
Zhang K, Zhang J, Gao ZG, Zhang D, Zhu L, Han GW, et al. Structure of the human P2Y12 receptor in complex with an antithrombotic drug. Nature 2014; 509: 115–8.
Schindler C, Mueller A, Bramlage P, Boecking W, Kirch W, Schweizer J . Comparison of selective AT1-receptor blockade versus ACE inhibition for restenosis prophylaxis in patients with peripheral occlusive arterial disease after stent angioplasty: a randomized, controlled, proof-of-concept study. Angiology 2007; 58: 710–6.
Goel D . Ticagrelor: The first approved reversible oral antiplatelet agent. Int J Appl Basic Med Res 2013; 3: 19–21.
Wong PC, Seiffert D, Bird JE, Watson CA, Bostwick JS, Giancarli M, et al. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding. Sci Transl Med 2017; 9: 371.
Chatterjee S, Sharma A, Mukherjee D . PAR-1 antagonists: current state of evidence. J Thromb Thrombolysis 2013; 35: 1–9.
Wu H, Qian J, Xu J, Sun A, Sun W, Wang Q, et al. Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China. Pharmacogenet Genomics 2012; 22: 887–90.
Acknowledgements
This study was supported by the project of Shanghai Key Specialty Clinical Pharmacy and China Scholarship Council (awarded to Ying XUE). The authors would like to acknowledge funding support from the NIH (No P30 DA035778) awarded to Xie's laboratory).
Author information
Authors and Affiliations
Corresponding authors
PowerPoint slides
Rights and permissions
About this article
Cite this article
Xue, Y., Feng, Zw., Li, Xy. et al. The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis. Acta Pharmacol Sin 39, 205–212 (2018). https://doi.org/10.1038/aps.2017.85
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2017.85
Keywords
This article is cited by
-
A retrospective study of the safety and efficacy of clopidogrel versus aspirin monotherapy one year after coronary stent implantation
BMC Pharmacology and Toxicology (2024)
-
Body weight, CYP2C19, and P2Y12 receptor polymorphisms relate to clopidogrel resistance in a cohort of Chinese ischemic stroke patients with aspirin intolerance
European Journal of Clinical Pharmacology (2020)
-
Insight of Captagon Abuse by Chemogenomics Knowledgebase-guided Systems Pharmacology Target Mapping Analyses
Scientific Reports (2019)
-
Structural insight into the serotonin (5-HT) receptor family by molecular docking, molecular dynamics simulation and systems pharmacology analysis
Acta Pharmacologica Sinica (2019)
